Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid symbols : TEVJF save search
Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
Published: 2021-11-12 (Crawled : 15:30) - prnewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
covid europe antibody covid-19
New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19
Published: 2021-11-08 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: 3.88%
H: 0.78%
C: 0.68%
covid casirivimab phase 3
FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
Published: 2021-10-14 (Crawled : 12:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.2%
H: 0.08%
C: -0.43%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: 1.07%
H: 2.19%
C: 0.47%
covid treatment fda casirivimab fda acceptance
Transdermal Drug Delivery - Global Market Trajectory Following COVID-19 Pandemic
Published: 2021-10-01 (Crawled : 17:00) - prnewswire.com
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
DRRX | $0.84 -3.58% -3.71% 58K
|
Health Technology
|
| O: 0.0%
H: 4.69%
C: 2.34%
ATRS | $5.59 0.0%
|
Health Technology
|
| O: 0.55%
H: 0.55%
C: 0.0%
covid drug drug delivery liver covid-19
New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19
Published: 2021-09-30 (Crawled : 05:00) - prnewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.02%
H: 0.2%
C: -0.31%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: 0.17%
H: 0.96%
C: -0.42%
covid results casirivimab covid-19
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
Published: 2021-09-29 (Crawled : 21:00) - prnewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.02%
H: 0.2%
C: -0.31%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: 0.17%
H: 0.96%
C: -0.42%
covid positive results casirivimab phase 3 trial trial results
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.